Darbepoetin-α enhances hepatectomy-associated stimulation of colorectal liver metastatic growth

Annals of Surgery

Volumn 252, Issue 1, 2010, Pages 131-141

  Rupertus, Kathrin ^a   Sperling, Jens ^a   Corsten, Marcus ^a   Scheuer, Claudia ^a   Nickels, Ruth M ^a   Schilling, Martin K ^a   Menger, Michael D ^a   Kollmar, Otto ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CANCER GROWTH; CAPILLARY DENSITY; CELL INTERACTION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; LIVER METASTASIS; LIVER RESECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VASCULARIZATION;

ANIMALS; APOPTOSIS; CASPASE 3; COLORECTAL NEOPLASMS; ERYTHROPOIETIN; FEMALE; FLOW CYTOMETRY; HEMATINICS; HEPATECTOMY; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; NEUTROPHIL INFILTRATION; TUMOR CELLS, CULTURED;

EID: 77954089924     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181e33915     Document Type: Article

References (49)

1. Kattan MW, Gönen M, Jarnagin WR, et al. A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann Surg. 2008;247:282-287. (Pubitemid 351156771)
2. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002; 235:759-766.
3. Imamura H, Seyama Y, Kokudo N, et al. One thousand fifty-six hepatecto-mies without mortality in 8 years. Arch Surg. 2003;138:1198-1206.
4. Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1803 consecutive cases over the past decade. Ann Surg. 2002;236:397-406.
5. Farges O, Malassagne B, Flejou JF, et al. Risk of major liver resection in patients with underlying chronic liver disease: a reappraisal. Ann Surg. 1999;229:210-215.
6. Novelli G, Rossi M, Pretagostini R, et al. A 3-year experience with Molecular Adsorbent Recirculating System (MARS): our results on 63 patients with hepatic failure and color Doppler US evaluation of cerebral perfusion. Liver Int. 2003;23(suppl 3):10-15.
7. Nishino M, Iimuro Y, Ueki T, et al. Hepatocyte growth factor improves survival after partial hepatectomy in cirrhotic rats suppressing apoptosis of hepatocytes. Surgery. 2008;144:374-384.
8. Macdougall IC. Optimizing the use of erythropoietic agents\pharmacoki- netic and pharmacodynamic considerations. Nephrol Dial Transplant. 2002; 17(suppl 5):66-70.
9. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol. 2008;141:14-31.
10. Kumral A, Baskin H, Yesilirmak DC, et al. Erythropoietin attenuates lipopo-lysaccharide-induced white matter injury in the neonatal rat brain. Neonatol-ogy. 2007;92:269-278. (Pubitemid 350125285)
11. Johnson DW, Pat B, Vesey DA, et al. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int. 2006;69:1806-1813.
12. Schmeding M, Boas-Knoop S, Lippert S, et al. Erythropoietin promotes hepatic regeneration after extended liver resection in rats. J Gastroenterol Hepatol. 2008;23:1125-1131.
13. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist. 2004;9(suppl 5):18-30.
14. Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255-1260.
15. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007;25:1027-1032.
16. Leyland-Jones B; BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 2003;4:459-460. (Pubitemid 37009952)
17. Hardee ME, Arcasoy MO, Blackwell KL, et al. Erythropoietin biology in cancer. Clin Cancer Res. 2006;12:332-339.
18. Newland AM, Black CD. Tumor progression associated with erythropoiesis-stimulating agents. Ann Pharmacother. 2008;42:1865-1870.
19. Tóvári J, Pirker R, Tímár J, et al. Erythropoietin in cancer: an update. Curr Mol Med. 2008;8:481-491.
20. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818-827.
21. Kollmar O, Schilling MK, Menger MD. Experimental liver metastasis: standards for local cell implantation to study isolated tumor growth in mice. Clin Exp Metastasis. 2004;21:453-460.
22. Kollmar O, Menger MD, Schilling MK. Macrophage inflammatory protein-2 contributes to liver resection-induced acceleration of hepatic metastatic tumor growth. World J Gastroenterol. 2006;12:858-867.
23. Le Minh K, Klemm K, Abshagen K, et al. Attenuation of inflammation and apoptosis by pre-and posttreatment of darbepoetin-alpha in acute liver failure of mice. Am J Pathol. 2007;170:1954-1963.
24. Kollmar O, Corsten M, Scheuer C, et al. Portal branch ligation induces a hepatic arterial buffer response, microvascular remodeling, normoxygenation, and cell proliferation in portal blood-deprived liver tissue. Am J Physiol Gastrointest Liver Physiol. 2007;292:G1534-G1542.
25. Kollmar O, Scheuer C, Menger MD, et al. Macrophage inflammatory pro-tein-2 promotes angiogenesis, cell migration, and tumor growth in hepatic metastasis. Ann Surg Oncol. 2006;13:263-275.
26. Lentschener C, Gomola A, Grabar S, et al. The effect of erythropoietin on allogeneic blood requirement in patients undergoing elective liver resection: a model simulation. Anesth Analg. 2004;98:921-926.
27. Bockhorn M, Fingas CD, Rauen U, et al. Erythropoietin treatment improves liver regeneration and survival in rat models of extended liver resection and living donor liver transplantation. Transplantation. 2008;86:1578-1585.
28. Schmeding M, Neumann UP, Boas-Knoop S, et al. Erythropoietin reduces ischemia-reperfusion injury in the rat liver. Eur Surg Res. 2007;39:189-197.
29. Sepodes B, Maio R, Pinto R, et al. Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat. Transpl Int. 2006;19:919-926.
30. Klemm K, Eipel C, Cantré D, et al. Multiple doses of erythropoietin impair liver regeneration by increasing TNF-alpha, the Bax to Bcl-xL ratio and apoptotic cell death. PLoS One. 2008;3:e3924.
31. Khuri FR. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med. 2007;356:2445-2448.
32. Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 2001;61:3561-3565.
33. Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int. 2000;58:647-657.
34. Selzer E, Wacheck V, Kodym R, et al. Erythropoietin receptor expression in human melanoma cells. Melanoma Res. 2000;10:421-426.
35. Hardee ME, Kirkpatrick JP, Shan S, et al. Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. Br J Cancer. 2005;93:1350-1355.
36. Yasuda Y, Fujita Y, Matsuo T, et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis. 2003;24:1021-1029.
37. Okazaki T, Ebihara S, Asada M, et al. Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia. 2008;10:932-939.
38. Rezaeian F, Wettstein R, Amon M, et al. Erythropoietin protects critically perfused flap tissue. Ann Surg. 2008;248:919-929.
39. Nakamatsu K, Nishimura Y, Suzuki M, et al. Erythropoietin/erythropoietin- receptor system as an angiogenic factor in chemically induced murine hepatic tumors. Int J Clin Oncol. 2004;9:184-188.
40. Contaldo C, Meier C, Elsherbiny A, et al. Human recombinant erythropoietin protects the striated muscle microcirculation of the dorsal skinfold from postischemic injury in mice. Am J Physiol Heart Circ Physiol. 2007;293: H274-H283.
41. Kupatt C, Hinkel R, Vachenauer R, et al. VEGF165 transfection decreases postischemic NF-kappa B-dependent myocardial reperfusion injury in vivo: role of eNOS phosphorylation. FASEB J. 2003;17:705-707.
42. Liu X, Xie W, Liu P, et al. Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia-reperfu-sion. Life Sci. 2006;78:2255-2264.
43. Lindenblatt N, Menger MD, Klar E, et al. Darbepoetin-alpha does not promote microvascular thrombus formation in mice: role of eNOS-dependent protection through platelet and endothelial cell deactivation. Arterioscler Thromb Vasc Biol. 2007;27:1191-1198.
44. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA. 1991;88:4651-4655.
45. Rupertus K, Kollmar O, Scheuer C, et al. Major but not minor hepatectomy accelerates engraftment of extrahepatic tumor cells. Clin Exp Metastasis. 2007;24:39-48.
46. Drixler TA, Borel Rinkes IH, Ritchie ED, et al. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res. 2000;60:1761-1765.
47. Oe H, Kaido T, Mori A, et al. Hepatocyte growth factor as well as vascular endothelial growth factor gene induction effectively promotes liver regeneration after hepatectomy in Solt-Farber rats. Hepatogastroenterology. 2005;52:1393-1397.
48. Yoon SS, Kim SH, Gonen M, et al. Profile of plasma angiogenic factors before and after hepatectomy for colorectal cancer liver metastases. Ann Surg Oncol. 2006;13:353-362.
49. Kollmar O, Junker B, Rupertus K, et al. Liver resection-associated macro-phage inflammatory protein-2 stimulates engraftment but not growth of colorectal metastasis at extrahepatic sites. J Surg Res. 2008;145:295-302.